enterococcus

''Enterococcus'' is a large genus of lactic acid bacteria of the phylum Bacillota. Enterococci are Gram-positive cocci that often occur in pairs ( diplococci) or short chains, and are difficult to distinguish from streptococci on physical characteristics alone. Two species are common commensal organisms in the intestines of humans: '' E. faecalis'' (90–95%) and '' E. faecium'' (5–10%). Rare clusters of infections occur with other species, including '' E. durans'' , ''E. casseliflavus'', '' E. gallinarum'', and ''E. raffinosus''.

Physiology and classification

Enterococci are facultative anaerobic organisms, i.e., they are capable of cellular respiration in both oxygen-rich and oxygen-poor environments. Though they are not capable of forming spores, enterococci are tolerant of a wide range of environmental conditions: extreme temperature (10–45 °C), pH (4.6–9.9), and high sodium chloride concentrations.

''E. faecium'' and ''E. faecalis'' can be differentiated based on their carbohydrate metabolism: ''E. faecium'' consistently metabolizes lactose but not melezitose or inositol, whereas ''E. faecalis'' reliably metabolizes sorbitol and sucrose but lacks the ability to utilize L-arabinose, melibiose, or raffinose. Less is known of other species; ''E. durans'' share most of the important carbohydrate metabolism with ''E. faecium''.

Enterococci exhibit variable hemolysis on blood agar. Differences occur between species, and between strains of species. More virulent organisms are more likely to exhibit alpha (partial) or beta (complete) hemolysis than less virulent specimens of ''Enterococcus'', which frequently exhibit gamma (absent) hemolysis.

History

Members of the genus ''Enterococcus'' (from Greek έντερο, ''éntero'' 'intestine' and κοκκος, ''coccos'' 'granule') were classified as group D ''Streptococcus'' until 1984, when genomic DNA analysis indicated a separate genus classification would be appropriate.

Evolution

This genus appears to have evolved to .

Pathology

Important clinical infections caused by ''Enterococcus'' include urinary tract infections (see '' Enterococcus faecalis''), bacteremia, bacterial endocarditis, diverticulitis, meningitis, and spontaneous bacterial peritonitis. Sensitive strains of these bacteria can be treated with ampicillin, penicillin and vancomycin. In catheterized patients receiving intensive care, ''Enterococcus'' spp., have been reported the dominant cause of urinary tract infections, particularly in patients treated with cephalosporin antibiotics. Recent work has shown that multiple genetically distinct ''Enterococcus'' sequence types, including antibiotic resistant and high risk clones, can coexist in the same urine sample from a single ICU patient, with the more virulent lineage often present only as a minority subpopulation - undetectable by standard diagnostics. Urinary tract infections can be treated specifically with nitrofurantoin, even in cases of vancomycin resistance.

Meningitis

Enterococcal meningitis is a rare complication of neurosurgery. It often requires treatment with intravenous or intrathecal vancomycin, yet it is debatable as to whether its use has any impact on outcome: the removal of any neurological devices is a crucial part of the management of these infections.
New epidemiological evidence has shown that enterococci are major infectious agent in chronic bacterial prostatitis. Enterococci are able to form biofilm in the prostate gland, making their eradication difficult. Cases of enterococcal meningitis, in the absence of trauma or surgery, should raise suspicion of an underlying intestinal pathology (e.g., strongyloidiasis).

Antibacterial resistance

From a medical standpoint, an important feature of this genus is the high level of intrinsic antibiotic resistance. Some enterococci are intrinsically resistant to β-lactam-based antibiotics (penicillins, cephalosporins, carbapenems), as well as many aminoglycosides. In the last two decades, particularly virulent strains of ''Enterococcus'' that are resistant to vancomycin ( vancomycin-resistant ''Enterococcus'', or VRE) have emerged in nosocomial infections of hospitalized patients, especially in the US. Other developed countries, such as the UK, have been spared this epidemic, and, in 2005, Singapore managed to halt an epidemic of VRE. Although quinupristin/ dalfopristin (Synercid) was previously indicated for treatment of VRE in the USA, the FDA approval for this indication has since been retracted. The rationale for the retraction of Synercid's indication for VRE was based upon poor efficacy in ''E. faecalis'', which is implicated in the vast majority of VRE cases. Tigecycline has also been shown to have antienterococcal activity, as has rifampicin.

''Bacillus haynesii'' CD223 and ''Advenella mimigardefordensis'' SM421 can inhibit the growth of ''Enterococcus'' spp.

Water quality

In bodies of water, the acceptable level of contamination is very low; for example in the state of Hawaii, and most of the United States, the limit for water off its beaches is a five-week geometric mean of 35 colony-forming units per 100 ml of water, above which the state may post warnings to stay out of the ocean. In 2004, measurement of enterococci took the place of fecal coliforms as the new American federal standard for water quality at public saltwater beaches and alongside ''Escherichia coli'' at freshwater beaches. It is believed to provide a higher correlation than fecal coliform with many of the human pathogens often found in city sewage.

References

External links

{{Authority control

Bacteria genera
Gram-positive bacteria
Pathogenic bacteria